NASDAQ:DBVT

DBV Technologies (DBVT) Stock Forecast, Price & News

$1.44

-0.03 (-2.04%)

(As of 09/21/2023 ET)

Compare

Today's Range: $1.40
▼
$1.46
50-Day Range: $1.40
▼
$1.79
52-Week Range: $1.08
▼
$2.37

Volume: 31,401 shs
Average Volume: 61,564 shs
Market Capitalization: $277.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

DBV Technologies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 386.1% Upside
$7.00 Price Target
Short Interest: Bearish
0.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$42,540 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.54) to ($0.52) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

862nd out of 965 stocks

Biological Products, Except Diagnostic Industry

135th out of 160 stocks

3.3

Analyst's Opinion

Consensus Rating
DBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, DBV Technologies has a forecasted upside of 386.1% from its current price of $1.44.
Amount of Analyst Coverage
DBV Technologies has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.61% of the outstanding shares of DBV Technologies have been sold short.
Short Interest Ratio / Days to Cover
DBV Technologies has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in DBV Technologies has recently increased by 0.85%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
DBV Technologies does not currently pay a dividend.
Dividend Growth
DBV Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DBVT.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DBV Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,540.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.71% of the stock of DBV Technologies is held by insiders.
Percentage Held by Institutions
Only 23.90% of the stock of DBV Technologies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for DBV Technologies are expected to grow in the coming year, from ($0.54) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DBV Technologies is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DBV Technologies is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DBV Technologies has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBVT Price History

30 days | 90 days | 365 days | Advanced Chart

DBVT Stock News Headlines

September 12, 2023 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

September 8, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Lower Thursday

September 22, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 30, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher Wednesday

August 30, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Gaining Tuesday

August 4, 2023 | benzinga.com

DBV Technologies And 3 Other Penny Stocks Insiders Are Buying

August 1, 2023 | msn.com

DBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric Studies

August 1, 2023 | finance.yahoo.com

DBV.PA - DBV Technologies S.A.

September 22, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 1, 2023 | markets.businessinsider.com

DBV Technologies SA – American (DBVT) Receives a Buy from JMP Securities

July 31, 2023 | finance.yahoo.com

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

July 25, 2023 | finance.yahoo.com

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

July 19, 2023 | finance.yahoo.com

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023

July 13, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Rise Sharply Thursday

June 22, 2023 | uk.finance.yahoo.com

DBV.F - DBV Technologies S.A.

June 22, 2023 | uk.finance.yahoo.com

DBVT - DBV Technologies S.A.

June 16, 2023 | finance.yahoo.com

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023

June 14, 2023 | finance.yahoo.com

DBV Technologies S.A. (DBVT) stock forecast and price target

June 10, 2023 | thestreet.com

DBV Technologies CEO: Peanut Allergy Patch Propelling Stock

June 8, 2023 | finanznachrichten.de

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming EAACI Congress 2023

June 8, 2023 | finance.yahoo.com

DBV Technologies to Participate in Upcoming EAACI Congress 2023

May 12, 2023 | finance.yahoo.com

A simple skin patch shows promise for preventing peanut allergies

May 11, 2023 | marketwatch.com

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin(TM) Peanut in Toddlers

May 11, 2023 | markets.businessinsider.com

Good News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy Patch

May 11, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for DBV Technologies SA – American (DBVT)

May 10, 2023 | finance.yahoo.com

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

May 9, 2023 | markets.businessinsider.com

DBV Technologies SA – American (DBVT) Gets a Buy from H.C. Wainwright

See More Headlines

Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Company Calendar

Last Earnings: 7/31/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DBVT
CUSIP: N/A
CIK: 1613780
Web: www.dbv-technologies.com
Phone: (315) 542-7878
Fax: 33-1-43-26-10-83
Employees: 88
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +386.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,270,000.00
Net Margins: N/A
Pretax Margin: -1,929.49%
Return on Equity: -54.06%
Return on Assets: -42.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.86
Quick Ratio: 5.86

Sales & Book Value

Annual Sales: $4.84 million
Price / Sales: 57.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.03 per share
Price / Book: 1.40

Miscellaneous

Outstanding Shares: 192,500,000
Free Float: 191,135,000
Market Cap: $277.20 million
Optionable: Optionable
Beta: 1.17

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Daniel Tassé (Age 63)
CEO & Director
Comp: $1.21M

Mr. Sébastien Robitaille (Age 53)
Chief Financial Officer
Comp: $335.17k

Dr. Pharis Mohideen (Age 58)
Chief Medical Officer
Comp: $725.12k

Mr. Pascal Wotling
Chief Technical Operations Officer & Chief Quality Officer

Ms. Michele F. Robertson
Chief Legal Officer

Joseph Becker
VP of Global Corp. Communications

Ms. Caroline Daniere (Age 48)
Chief HR Officer & Chief of Staff

Dr. Wence Agbotounou
Chief Clinical Trial Officer & Sr. VP

Mr. Edward P. Jordan M.B.A. (Age 55)
Sr. VP of Commercial Operations North America

Alan Kerr
Sr. VP & Head of Global Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DBVT Stock - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DBVT shares.
View DBVT analyst ratings or view top-rated stocks.
What is DBV Technologies' stock price forecast for 2023?: 4 brokerages have issued 1 year price targets for DBV Technologies' shares. Their DBVT share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 386.1% from the stock's current price.
View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts.
How have DBVT shares performed in 2023?: DBV Technologies' stock was trading at $1.53 at the start of the year. Since then, DBVT shares have decreased by 5.9% and is now trading at $1.44.
View the best growth stocks for 2023 here.
When is DBV Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DBVT earnings forecast.
How were DBV Technologies' earnings last quarter?: DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Monday, July, 31st. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $1 million.
What other stocks do shareholders of DBV Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?: DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."
Who are DBV Technologies' major shareholders?: DBV Technologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (1.62%), BlackRock Inc. (0.53%), Optiver Holding B.V. (0.02%), BNP Paribas Arbitrage SNC (0.02%), Citadel Advisors LLC (0.02%) and Envestnet Asset Management Inc. (0.01%). Insiders that own company stock include Daniel B Soland, Pharis Mohideen and Timothy E Morris.
View institutional ownership trends.
How do I buy shares of DBV Technologies?: Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is DBV Technologies' stock price today?: One share of DBVT stock can currently be purchased for approximately $1.44.
How much money does DBV Technologies make?: DBV Technologies (NASDAQ:DBVT) has a market capitalization of $277.20 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.
How can I contact DBV Technologies?: DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83.

This page (NASDAQ:DBVT) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial